我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
32
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1916
已完成
10
31.3%
招募中
3.1%
终止
6.3%
NMPA
National Medical Products Administration
- GlycoNex Inc. and Nippon Kayaku Co., Ltd. have entered a collaboration to advance GNX201-ADC, a next-generation antibody-drug conjugate designed for solid tumor treatment. - The ADC candidate features protease-activated technology that remains stable in circulation and selectively activates in the tumor microenvironment to minimize toxicity. - GNX201-ADC leverages GlycoNex's "Antibody Lock" technology, incorporating a pro-ADC design that targets tumor-associated glycan antigens while sparing healthy tissue. - The partnership combines GlycoNex's glycan-directed antibody expertise with Nippon Kayaku's oncology pharmaceutical development capabilities to accelerate preclinical development.
